Search
andthrough outline tiger tickets a network tiger games gathers of international distributors and strategic partners inover 75 countries worldwide. For further information please see theCompany's website:. of ADR's used in Computing earnings per ADR.20,856,868 20,634,975 20,855,638 19,837,083The above financial statements have been prepared in accordance with theprinciples of International Financial Reporting Standards and the Company'saccounting policies but do not constitute an interim financial report asdefined in IAS 34 (Interim Financial Reporting). Also, whencompared with quarter 1 2009, this quarter's revenues have grown by 2.7%."From a profitability perspective I am particularly pleased to announce aprofit of $3 million for the quarter, the first time this has beenachieved in the history of the Company."Since quarter end we have achieved two key milestones. Whilst revenues have fallen by 5.7% when compared to quarter 2,2008, this was in line with our expectations. This was largelyattributable to a decline in our haemostasis revenues which we hadanticipated in advance of Destiny Max being launched. On the other hand,we have continued to see particularly strong growth in our point-of-carerevenues, which have increased by 50% quarter on quarter.
Net incomefor the quarter has doubled to $3.0 million, or $0.14 per share (ADR)from $1.5 million, or $0.07 per share (ADR) versus the second quarter of2008.During the quarter, the Company generated more than $4 million of cashfrom operations and free cash flow of more than $2.2 million thusaccounting for the increase in cash from $2.6m at the end of the firstquarter of 2009 to $4.8m at the end of this quarter.Ronan O'Caoimh, CEO, commented, "We are pleased with the results thisquarter tiger baseball tickets . The tax chargefor the quarter was $0.5 million representing an effective tax rate of14.0%.Operating profit for the quarter amounted to $3.8 million, whichrepresents an increase of 66% over the second quarter of 2008 tiger game tickets . This was offset by a 13% decreasein Clinical Laboratory revenues, primarily attributable to a fall inhaemostasis revenues in advance of the launch of Destiny Max and lowerFitzgerald revenues.Revenues for the three months by key product area were as follows :200820082009% Increase/Quarter 2 Quarter 2 Quarter 2(decrease)Adjusted* US$'000 US$'000 US$'000Total Clinical Laboratory 32,26030,32926,394 (13.0%)Point-of-Care4,036 3,938 5,90850%Total 36,29634,26732,302(5.7%)* Revenues for the second quarter of 2008 have been adjusted to reflectexchange rates prevailing in the second quarter of 2009Gross profit for the quarter amounted to $14.7 million representing agross margin of approximately 46% which is an improvement of 0.9% overthe same period in 2008 red socks . This continues the trend of lower indirect costs due tothe impact of the cost saving measures, lower depreciation andamortization charges and more favourable exchange rates red socks tickets . Research and Development expenses amounted to$1.8m, representing a decrease of 8%. SG&A expenses have fallen by 24%from $11.8 million in the second quarter of 2008 to $9.0 million in thecurrent quarter.
Point-of-Care revenues increasedsubstantially, growing by 50%, largely driven by increased HIV sales inthe key markets of Africa and the USA tiger . DUBLIN, IRELAND, Jul 23 (MARKET WIRE) -- Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturerof diagnostic products for the point-of-care and clinical laboratorymarkets, today announced results for the quarter ended June 30, 2009.On a constant currency basis, revenues for the quarter decreased to $32.3million from $34.3 million, compared to the same period last year,representing a difference of 5.7% stadium . FickenscherCFOAuxilium Pharmaceuticals, Inc.(484) 321-5900Email ContactWilliam Q detroittigers . Sargent, Jr.V.P., I.R.Auxilium Pharmaceuticals, Inc.(484) 321-5900Email ContactCopyright 2009, Market Wire, All rights reserved.-0- david ortiz . However, while Auxilium may electto update these forward-looking statements at some point in the future,Auxilium specifically disclaims any obligation to do so. Theseforward-looking statements should not be relied upon as representingAuxilium's assessments as of any date subsequent to the date of thisrelease.For More Information, Contact:James E.
Auxilium anticipates that subsequent events and developments willcause Auxilium's assessments to change buy tiger tickets . Given these risks and uncertainties, any or all of theseforward-looking statements may prove to be incorrect jason varitek . Therefore, youshould not rely on any such factors or forward-looking statements.In addition, forward-looking statements provide Auxilium's expectations,plans or forecasts of future events and views as of the date of thisrelease tiger games . XIAFLEX is in phase IIbof development for the treatment of Peyronie's disease and is in phase IIof development for treatment of Frozen Shoulder syndrome (AdhesiveCapsulitis) tiger game tickets . Auxilium's transmucosal film product candidate for thetreatment of overactive bladder (AA4010) and its fentanyl pain productusing its transmucosal delivery system are in phase I of development. TheCompany is currently seeking a partner to further develop these productcandidates.
Auxilium has rights to additional pain products and productsfor hormone replacement and urologic disease using its transmucosal filmdelivery system cheap tiger tickets . is a specialty biopharmaceutical companywith a focus on developing and marketing to urologists, endocrinologists,orthopedists and select primary care physicians red socks . Auxilium marketsTestim(R) 1%, a topical testosterone gel, for the treatment ofhypogonadism through its approximately 190-person sales and marketingteam Auxilium has five projects in clinical development red socks tickets . Auxilium also has options to all indications usingXIAFLEX for non-topical formulations .
- In: General